REOLYSIN + Carboplatin + Paclitaxel
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Melanoma
Conditions
Metastatic Melanoma
Trial Timeline
Sep 1, 2009 → Oct 1, 2014
NCT ID
NCT00984464About REOLYSIN + Carboplatin + Paclitaxel
REOLYSIN + Carboplatin + Paclitaxel is a phase 2 stage product being developed by Oncolytics Biotech for Metastatic Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00984464. Target conditions include Metastatic Melanoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00984464 | Phase 2 | Completed |
Competing Products
20 competing products in Metastatic Melanoma